Ronald Simeone

Ronald Simeone is the president of Simeone Associates, Inc., a New York firm specializing in the development of drug and crime control policy. He has more than thirty years experience in the field and is a leading authority on the evaluation of federal counter-narcotics initiatives

Dr. Simeone conducted extensive research for the Executive Office of the President, Office of National Drug Control Policy, on procedures designed to measure the success of United States supply and demand reduction efforts, and was the principal architect of their Performance Measures of Effectiveness system.

Working in concert with representatives of the United States Coast Guard, Customs and Border Protection (Border Patrol, Office of Field Operations, and Air & Marine), and Immigration and Customs Enforcement, he developed a strategic plan and corresponding performance measures for the Department of Homeland Security, Office of Counternarcotics Enforcement.

The United States Department of Justice, Bureau of Justice Assistance, partnered with Dr. Simeone to evaluate the effectiveness of state monitoring programs in reducing prescription drug diversion and abuse. His findings continue to provide guidance to program initiatives in this area.

Dr. Simeone worked closely with the United States Department of Justice, National Drug Intelligence Center, to estimate the economic impact of illicit drug use on American society, and later, with that same agency, to estimate the quantity of drug-related bulk cash exiting the United States by way of the Southwest border.

His most recent work has involved the development of methods for defining and quantifying prescription opioid diversion, and a study applying these methods has been completed for the Executive Office of the President, Office of National Drug Control Policy.

Dr. Simeone held deputy commissioner-level positions in two State of New York agencies before becoming a private consultant in 1992. While in state government he supervised the conduct of large scale population surveys, the development of automated quality assurance systems used to monitor the performance of drug treatment programs, and the activities of a New York City-based operation that collected intelligence on drug trafficking behavior.